Clinical Impact of Continuous Glucose Monitoring in Noninsulin Treated Type 2 Diabetes: A Review

Diabetes Technology & Therapeutics 2026

View at publisher
Authors: Grazia Aleppo, Anders L. Carlson, Janet B. McGill, Hamza Alshannaq, Rodolfo J. Galindo, Davida Kruger, Carol J. Levy, Jéssica Yumi Matuoka, Sabrina Ilham, Guillermo Umpierrez, Gregory J. Norman
DOI: 10.1177/15209156251414980
Cited by: 3
References: 73

Abstract

Continuous glucose monitoring (CGM) technology is becoming increasingly available to people with diabetes using insulin therapy; however, availability for people with type 2 diabetes (T2D) not on insulin remains limited. For people with T2D, there is strong evidence of glycemic benefit with CGM use for those treated with insulin, and CGM is accepted as standard of care. This review explores the impact of CGM use on glycemic and patient-reported outcomes in noninsulin treated populations with T2D, reporting outcomes from 10 identified randomized controlled trials and 15 nonrandomized studies. We report evidence that supports the use of this technology in people with T2D not using insulin.

Fields of Study & Subjects

Diabetes Management and Research Hyperglycemia and glycemic control in critically ill and hospitalized patients Mobile Health and mHealth Applications

Publication details

Journal / source
Diabetes Technology & Therapeutics
Publisher
SAGE Publications
Volume
28
Issue
7
Pages
639–657
Publication date
23 January 2026
Language
EN